雑誌文献を検索します。書籍を検索する際には「書籍検索」を選択してください。

検索

書誌情報 詳細検索 by 医中誌

Japanese

A case of an elderly female with anti-aquaporin 4 antibody-positive optic neuritis treated with satralizumab Daisuke Shinohara 1 , Takaaki Hayashi 1 , Teruaki Tokuhisa 1 , Machiko Suda 2 , Tadashi Nakano 3 1Department of Ophthalmology, The Jikei University Katsushika Medical Center 2Department of Gastroenterology and Hepatology, The Jikei University Katsushika Medical Center 3Department of Ophthalmology, The Jikei University School of Medicine pp.352-360
Published Date 2023/3/15
DOI https://doi.org/10.11477/mf.1410214741
  • Abstract
  • Look Inside
  • Reference

Abstract Purpose:This case reports an elderly female with anti-aquaporin 4(AQP4)antibody-positive optic neuritis(ON)treated with satralizumab, an anti-interleukin-6(IL-6)receptor monoclonal antibody, as relapse prophylaxis for neuromyelitis optica spectrum disorder.

Case:An 81-year-old woman was aware of sudden visual field defects in the left eye(LE)and presented to our hospital for further examination on day 7 from onset.

Findings and clinical courses:Best corrected visual acuity(BCVA)was 0.9 in the right eye(RE)and no light perception in the LE. The left relative afferent pupillary defect(RAPD)was present. Brain/orbital MRI STIR images showed high signal intensity in the left optic nerve. After serological testing, she was diagnosed with anti-AQP4 antibody-positive ON. BCVA in the LE improved to 0.07 after steroid semi-pulse therapy and immunoadsorption therapy, followed by tapering oral steroids, and low-dose oral steroid treatment was continued for 21 months as a maintenance treatment. Sixteen months later, the same acute treatment was performed again due to the onset of the RE and recurrence in the LE. During the second treatment, satralizumab was administered during steroid tapering. There was no relapse during the 5 months of follow-up. A further five months later, she died of exacerbation of pre-existing bowel obstruction and heart disease.

Conclusions:We experienced a case of an elderly woman who was administered with satralizumab for bilateral anti-AQP4 antibody-positive ON. After treated, it was considered important to adequately monitor not only therapeutic efficacy but also side effects.


Copyright © 2023, Igaku-Shoin Ltd. All rights reserved.

基本情報

電子版ISSN 1882-1308 印刷版ISSN 0370-5579 医学書院

関連文献

もっと見る

文献を共有